Kelun's Sac-TMT lung cancer treatment approved in China

Sichuan Kelun Pharmaceutical (SZSE:002422) announced that its subsidiary, Kelun-Biotech, received approval from China's National Medical Products Administration (NMPA) for sac-TMT (formerly SKB264/MK-2870), branded as "Jiatailai," as a second-line treatment for EGFR-mutated non-small cell lung cancer (NSCLC). The approval marks sac-TMT as the first TROP2 ADC drug approved for lung cancer treatment globally. The approval was based on the OptiTROP-Lung03 clinical trial. Data demonstrated statistically significant improvements in Objective Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS) compared to docetaxel. Kelun-Biotech granted Merck (MSD) exclusive rights to develop, manufacture, and commercialize sac-TMT outside Greater China in May 2022.